Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8364082 | 0.83 | NOTUM (0.43) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL17498074 | 0.81 | NOTUM (0.40) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL29627844 | 0.81 | NOTUM (0.40) | NOTUMPARP1PARP10PARP11 | |
| SCHEMBL5335092 | 0.81 | NOTUM (0.40) | NOTUMPARP1PARP10PARP11 | |
| SCHEMBL27707619 | 0.77 | GRIA1 (0.37) | PARP1PARP10PARP11BCHE | |
| SCHEMBL31161534 | 0.74 | S1PR1 (0.36) | NOTUMS1PR1S1PR3 | |
| SCHEMBL1031349 | 0.74 | PARP1 (0.56) | NOTUMPARP1PARP10PARP11BRD4 | |
| Indoline SCHEMBL22344732 | 0.73 | PARP10 (0.34) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL30916119 | 0.73 | NOTUM (0.47) | NOTUMPARP1PARP10PARP11BCHE | |
| SCHEMBL20539302 | 0.73 | NOTUM (0.47) | NOTUMPARP1PARP10PARP11BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126978-A1 | PROCESS TO PREPARE OCTOPAMINE SULFATE | DIRECTOR, NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH, GUWAHATI (NIPER-G) (IN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023112055-A1 | NEW SYNTHETIC PROCESS DESIGN FOR THE SYNTHESIS OF CARBOXY TORMIFENE AND PURITY ANALYSIS TO STRENGTHEN ANTIDOPING TESTING | DIRECTOR, NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH, GUWAHATI (NIPER-G) (IN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2021028935-A1 | HETEROCYCLIC COMPOUNDS, AND THEIR USE AS ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | DR REDDY'S INSTITUTE OF LIFE SCIENCES (IN) | 2021-02-18 | — | — | WO | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NOTUM 3827/4885PARP1 4420/4885PARP10 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.